Treatment of chronic venous disease with flavonoids: Recommendations for treatment and further studies

Phlebology

Volumn 28, Issue 6, 2013, Pages 308-319

  Rabe, E ^a   Guex, J J ^b   Morrison, N ^c   Ramelet, A A ^d   Schuller Petrovic, S ^e   Scuderi, A ^f   Staelens, I ^g   Pannie, F ^h  

^a UNIVERSITY OF BONN   (Germany)

^b Cabinet de Phlebologie   (France)

^c Morrison Vein Institute   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e VENEX Vein Centre   (Austria)

^f Vascular Research Institute of Sorocaba   (Brazil)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^h UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic venous disease; Chronic venous insufficiency; Flavonoids; Inflammation; Venoactive drugs

Indexed keywords

AS 195; DIOSMETIN; DIOSMIN; FLAVONOID; GLUCOSIDE; GLUCURONIDE; HESPERIDIN; HIDROSMIN; HYPOXIA INDUCIBLE FACTOR; KAEMPFEROL; MATRIX METALLOPROTEINASE; MONOXERUTIN; NITRIC OXIDE; OXYRUTIN; PLACEBO; PROANTHOCYANIDIN; PYCNOGENOL; QUERCETIN; SERINE PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ARTICLE; BASIC RESEARCH; CELL INFILTRATION; CHRONIC DISEASE; CHRONIC VEIN INSUFFICIENCY; CLINICAL EFFECTIVENESS; COMPRESSION STOCKING; COMPRESSION THERAPY; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GASTROCNEMIUS MUSCLE; HUMAN; HUNGARY; HYPERTENSION; HYPOXIA; LEG EDEMA; LEG PAIN; LEG SWELLING; LEUKOCYTE MIGRATION; LONG TERM CARE; MOLECULAR PATHOLOGY; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN EDEMA; TREATMENT DURATION; ULCER; ULCER HEALING; UNSPECIFIED SIDE EFFECT; VEIN BLOOD FLOW; VEIN DISEASE; VEIN TONE; VEIN VALVE; VENOUS REFLUX; VOLUMETRY;

CHRONIC VENOUS DISEASE; CHRONIC VENOUS INSUFFICIENCY; FLAVONOIDS; INFLAMMATION; VENOACTIVE DRUGS;

CHRONIC DISEASE; FLAVONOIDS; HUMANS; VENOUS INSUFFICIENCY;

EID: 84890248876     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1177/0268355512471929     Document Type: Article

References (102)

1. Eklof B, Perrin M, Delis KT, et al. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009;49:498-501
2. Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008;27:1-59
3. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011;41:117-25
4. van Korlaar I, Vossen C, Rosendaal F, et al. Quality of life in venous disease. Thromb Haemost 2003;90:27-35
5. Kaplan RM, Criqui MH, Denenberg JO, et al. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg 2003;37:1047-53
6. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997;48:67-9
7. Rabe E, Pannier F. Societal costs of chronic venous disease in CEAP C4, C5, C6 disease. Phlebology 2010;25(Suppl. 1):64-7
8. Maurins U, Hoffmann BH, Losch C, et al. Distribution and prevalence of reflux in the superficial and deep venous system in the general population - results from the Bonn Vein Study, Germany. J Vasc Surg 2008;48:680-7
9. Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40,095 patients. Phlebology 2003;18:110-22
10. Labropoulos N, Leon L, Kwon S, et al. Study of the venous reflux progression. J Vasc Surg 2005;41:291-5
11. Bergan JJ, Schmid-Schonbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006;355:488-98
12. Raffetto JD, Qiao X, Koledova VV, et al. Prolonged increases in vein wall tension increase matrix metallo-proteinases and decrease constriction in rat vena cava: potential implications in varicose veins. J Vasc Surg 2008;48:447-56
13. Kowalewski R, Malkowski A, Sobolewski K, et al. Evaluation of transforming growth factor-beta signaling pathway in the wall of normal and varicose veins. Pathobiology 2010;77:1-6
14. Ghaderian SM, Lindsey NJ, Graham AM, et al. Pathogenic mechanisms in varicose vein disease: the role of hypoxia and inflammation. Pathology 2010;42:446-53
15. Lim CS, Kiriakidis S, Paleolog EM, et al. Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg 2012;55:1427-39
16. Lim CS, Qiao X, Reslan OM, et al. Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 2011;53:764-73
17. Schuller-Petrovic S, Siedler S, Kern T, et al. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol 1997;122:772-8
18. Pascarella L, Schmid Schonbein GW. Causes of tele-ngiectasias, reticular veins, and varicose veins. Semin Vasc Surg 2005;18:2-4
19. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res 2009;123(Suppl. 4):S66-71
20. Miteva M, Romanelli P, Kirsner RS. Lipodermatosclero-sis. Dermatol Ther 2010;23:375-88
21. Sippel K, Mayer D, Ballmer B, et al. Evidence that venous hypertension causes stasis dermatitis. Phlebol-ogy 2012;26:361-5
22. Herouy Y, Mellios P, Bandemir E, et al. Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 2001;25:198-205
23. Pappas PJ, You R, Rameshwar P, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg 1999;30:1129-45
24. Kim D, Kang WH. Role of dermal melanocytes in cutaneous pigmentation of stasis dermatitis: a histo-pathological study of 20 cases. J Korean Med Sci 2002;17:648-54
25. Caggiati A, Rosi C, Franceschini M, et al. The nature of skin pigmentations in chronic venous insufficiency: a preliminary report. Eur J Vasc Endovasc Surg 2008;35: 111-8
26. Caggiati A, Franceschini M, Heyn R, et al. Skin erythro-diapedesis during chronic venous disorders. J Vasc Surg 2011;53:1649-53
27. Caggiati A, Rosi C, Casini A, et al. Skin iron deposition characterises lipodermatosclerosis and leg ulcer. Eur J Vasc Endovasc Surg 2010;40:777-82
28. Liu YC, Margolis DJ, Isseroff RR. Does inflammation have a role in the pathogenesis of venous ulcers? A critical review of the evidence. J Invest Dermatol 2011;131:818-27
29. Berridge D, Bradbury AW, Davies AH, et al. Recommendations for the referral and treatment of patients with lower limb chronic venous insufficiency (including varicose veins). Phlebology 2011;26:91-3
30. Zimmet S. Recommendations for the referral and treatment of patients with lower limb chronic venous insufficiency. Phlebology 2011;26:89-90
31. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011;53:2S-48S
32. Gillespie DL, Kistner B, Glass C, et al. Venous ulcer diagnosis, treatment, and prevention of recurrences. J Vasc Surg 2010;52:8S-14S
33. Moffatt C, Kommala D, Dourdin N, et al. Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence. Int Wound J 2009;6:386-93
34. O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009: CD000265
35. Gloviczki P, Gloviczki ML. Evidence on efficacy of treatments of venous ulcers and on prevention of ulcer recurrence. Perspect Vasc Surg Endovasc Ther 2009;21:259-68
36. Palfreyman SJ, Michaels JA. A systematic review of compression hosiery for uncomplicated varicose veins. Phlebology 2009;24(Suppl. 1):13-33
37. Lurie F, Kistner RL. Trends in patient reported outcomes of conservative and surgical treatment of primary chronic venous disease contradict current practices. Ann Surg 2011;254:363-7
38. Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005;33:309-19
39. Zilva SS. Vitamin P. Biochem J 1937;31:915-9
40. Gonzalez R, Ballester I, Lopez-Posadas R, et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr 2011;51:331-62
41. Ramelet AA. Venoactive drugs. In: Goldman MP, Guex JJ, Weiss RA, eds. Sclerotherapy. 5th edn. Edinburgh: W.B. Saunders, 2011;369-77
42. Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia Vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung 2000;50:109-17
43. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-68
44. Gohel MS, Davies AH. Pharmacological treatment in patients with C4, C5 and C6 venous disease. Phlebology 2010;25(Suppl 1):35-41
45. Poynard T, Valterio C. Meta-analysis of hydroxyethyl-rutosides in the treatment of chronic venous insufficiency. Vasa 1994;23:244-50
46. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endo-vasc Surg 2005;30:198-208
47. de Jongste AB, Jonker JJ, Huisman MV, et al. A double blind three center clinical trial on the short-term efficacy of 0-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thromb Haemost 1989;62:826-9
48. Rabe E, Stucker M, Esperester A, et al. Efficacy and tol-erability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency - results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg 2011;41:540-7
49. Kalus U, Koscielny J, Grigorov A, et al. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs R D 2004;5:63-71
50. Monsieur R, Van Snick G. [Efficacy of the red vine leaf extract AS 195 in chronic venous insufficiency]. Praxis (Bern 1994) 2006;95:187-90
51. Schaefer E, Peil H, Ambrosetti L, et al. Oedema protective properties of the red vine leaf extract AS 195 (Folia Vitis viniferae) in the treatment of chronic venous insufficiency. A 6-week observational clinical trial. Arzneimittelforschung 2003;53:243-6
52. Nuzum DS, Gebru TT, Kouzi SA. Pycnogenol for chronic venous insufficiency. Am J Health Syst Pharm 2011;68:1589-90, 1599-1601
53. Schoonees A, Visser J, Musekiwa A, et al. Pycnogen-ol((R)) for the treatment of chronic disorders. Cochrane Database Syst Rev 2012;2:CD008294
54. Guillot B, Guilhou JJ, de Champvallins M, et al. A long term treatment with a venotropic drug. Results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol 1989;8:67-71
55. ′-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol 2002;58:395-402
56. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol 2009;7:303-8
57. Nees S, Weiss DR, Reichenbach-Klinke E, et al. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. Arzneimittelforschung 2003;53:330-41
58. Badger C, Preston N, Seers K, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004:CD003140
59. Martinez MJ, Bonfill X, Moreno RM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2005:CD003229
60. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice, 1996. www.ICH.org
61. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332
62. Guex JJ. Importance of patient-reported outcomes in chronic venous disorders. Phlebology 2012;27(Suppl. 1):136-8
63. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 1996;5:539-54
64. Guex JJ, Zimmet SE, Boussetta S, et al. Construction and validation of a patient-reported outcome dedicated to chronic venous disorders: SQOR-V (specific quality of life and outcome response - venous). J Mal Vasc 2007;32:135-47
65. Lamping DL, Schroter S, Kurz X, et al. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 2003;37:410-9
66. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
67. Rabe E, Pannier F. Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits. Phlebology 2012;27(Suppl. 1):114-8
68. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg 2000;31:1307-12
69. Passman MA, McLafferty RB, Lentz MF, et al. Validation of Venous Clinical Severity Score (VCSS) with other venous severity assessment tools from the American Venous Forum, National Venous Screening Program. J Vasc Surg 2011;54:2S-9S
70. Vasquez MA, Rabe E, McLafferty RB, et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg 2010;52:1387-96
71. Perrin M, Guex JJ. Edema and leg volume: methods of assessment. Angiology 2000;51:9-12
72. Rabe E, Stucker M, Ottillinger B. Water displacement leg volumetry in clinical studies - a discussion of error sources. BMC Med Res Methodol 2010;10:5
73. te Slaa A, Mulder P, Dolmans D, et al. Reliability and reproducibility of a clinical application of a simple technique for repeated circumferential leg measurements. Phlebology 2010;26:14-9
74. Volikova AI, Edwards J, Stacey MC, et al. High-frequency ultrasound measurement for assessing post-thrombotic syndrome and monitoring compression therapy in chronic venous disease. J Vasc Surg 2009;50:820-5
75. Uhl JF, Cornu-Thenard A, Satger B, et al. Clinical analysis of the corona phlebectatica. J Vasc Surg 2011;55:150-3
76. Stucker M, Schobe MC, Hoffmann K, et al. Cutaneous microcirculation in skin lesions associated with chronic venous insufficiency. Dermatol Surg 1995;21: 877-82
77. Aguilar Peralta GR, Arevalo Gardoqui J, Llamas Macias FJ, et al. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. Int Angiol 2007;26:378-84
78. Junger M, Steins A, Hahn M, et al. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 2000;7:S3-12
79. Ruckley CV, Evans CJ, Allan PL, et al. Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. J Vasc Surg 2002;36:520-5
80. Navarro TP, Delis KT, Ribeiro AP. Clinical and hemody-namic significance of the greater saphenous vein diameter in chronic venous insufficiency. Arch Surg 2002;137:1233-7
81. Lurie F, Comerota A, Eklof B, et al. Multicenter assessment of venous reflux by duplex ultrasound. J Vasc Surg 2011;55:437-45
82. Criado E, Farber MA, Marston WA, et al. The role of air plethysmography in the diagnosis of chronic venous insufficiency. J Vasc Surg 1998;27:660-70
83. Bays RA, Healy DA, Atnip RG, et al. Validation of air plethysmography, photoplethysmography, and duplex ultrasonography in the evaluation of severe venous stasis. J Vasc Surg 1994;20:721-7
84. van Bemmelen PS, Mattos MA, Hodgson KJ, et al. Does air plethysmography correlate with duplex scanning in patients with chronic venous insufficiency? J Vasc Surg 1993;18:796-807
85. Verkruysse W, Svaasand LO, Nelson JS. Remote plethysmographic imaging using ambient light. Opt Express 2008;16:21434-45
86. Pokrovskii AV, Sapelkin SV, Galaktionova LA, et al. [The assessment of medical therapy effectiveness of patients with lower limb chronic venous insufficiency: the results of prospective study with Ginkor Fort]. Angiol Sosud Khir 2005;11:47-52
87. Chen H, Yao K, Nadas J, et al. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One 2012;7:e38261
88. Korthuis RJ, Unthank JL. Experimental models to investigate inflammatory processes in chronic venous insufficiency. Microcirculation 2000;7:S13-22
89. Jones GT, Grant MW, Thomson IA, et al. Characterization of a porcine model of chronic superficial varicose veins. J Vasc Surg 2009;49:1554-61
90. Cova D, De Angelis L, Giavarini F, et al. Pharmacoki-netics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992;30:29-33
91. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol 2008;4:17-35
92. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, et al. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011;11:298-344
93. Allegra C. Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospi-talization - an Italian perspective. Curr Med Res Opin 2003;19:761-9
94. Glinski W, Chodynicka B, Roszkiewicz J, et al. [Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized]. Minerva Cardioangiol 2001;49:107-14
95. Simka M, Majewski E. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. Am J Clin Dermatol 2003;4:573-81
96. Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiol-ogy 2002;53:257-63
97. Danielsson G, Jungbeck C, Peterson K, et al. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 2002;23:73-6
98. Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia 2000;71:236-44
99. Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85
100. Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung 1996;46:478-82
101. MacLennan WJ, Wilson J, Rattenhuber V, et al. Hydro-xyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52
102. Dominguez C, Brautigam I, Gonzalez E, et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Curr Med Res Opin 1992;12:623-30